Biomarkers For Predicting And Assessing Responsiveness Of Thyroid And Kidney Cancer Subjects To Lenvatinib Compounds

  • Published: Apr 17, 2018
  • Earliest Priority: Jun 03 2011
  • Family: 14
  • Cited Works: 1488
  • Cited by: 0
  • Cites: 432
  • Additional Info: Cited Works

The full document isn't yet available to us from the patent office.


Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.


Information currently unavailable.

Download PDF
Document Preview
Document History
  • Publication: Apr 17, 2018
  • Application: May 31, 2012
    US US 201214122339 A
  • Priority: May 31, 2012
    US US 201214122339 A
  • Priority: May 31, 2012
    US US 2012/0040183 W
  • Priority: Jun 3, 2011
    US US 201161493294 P

Download Citation

Sign in to the Lens